Do analysts rate MEDP or STVN?

Medpace presently has a consensus target price of $595.20, suggesting a potential upside of 1.31%. Given Medpace's higher probable upside, equities analysts plainly believe Medpace is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medpace 0 Sell rating(s) 9 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25 Stevanato Group 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.86

Which has stronger earnings & valuation, MEDP or STVN?

Medpace has higher revenue and earnings than Stevanato Group. Medpace is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 6.48 $451.12M $17.06 34.44 Stevanato Group €1.23B 5.19 €158.21M €0.56 37.47

Is MEDP or STVN more profitable?

Medpace has a net margin of 17.67% compared to Stevanato Group's net margin of 10.99%. Medpace's return on equity of 110.15% beat Stevanato Group's return on equity. Company Net Margins Return on Equity Return on Assets Medpace 17.67% 110.15% 24.84% Stevanato Group 10.99% 10.43% 6.16%

Does the media prefer MEDP or STVN?

In the previous week, Medpace had 1 more articles in the media than Stevanato Group. MarketBeat recorded 9 mentions for Medpace and 8 mentions for Stevanato Group. Medpace's average media sentiment score of 1.47 beat Stevanato Group's score of 0.54 indicating that Medpace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stevanato Group 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate RVTY or STVN?

Revvity presently has a consensus target price of $116.57, indicating a potential downside of 6.34%. Given Revvity's higher probable upside, analysts clearly believe Revvity is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revvity 0 Sell rating(s) 14 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.22 Stevanato Group 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.86

Which has stronger valuation and earnings, RVTY or STVN?

Revvity has higher revenue and earnings than Stevanato Group. Stevanato Group is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Revvity $2.91B 4.77 $241.20M $2.10 59.27 Stevanato Group €1.23B 5.19 €158.21M €0.56 37.47

Does the media refer more to RVTY or STVN?

In the previous week, Revvity had 15 more articles in the media than Stevanato Group. MarketBeat recorded 23 mentions for Revvity and 8 mentions for Stevanato Group. Revvity's average media sentiment score of 0.82 beat Stevanato Group's score of 0.54 indicating that Revvity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revvity 8 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stevanato Group 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ICLR or STVN?

Icon currently has a consensus target price of $170.40, suggesting a potential upside of 0.64%. Given Icon's higher probable upside, research analysts clearly believe Icon is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Icon 2 Sell rating(s) 7 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.41 Stevanato Group 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.86

Which has better earnings and valuation, ICLR or STVN?

Icon has higher revenue and earnings than Stevanato Group. Stevanato Group is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Icon $8.29B 1.56 $229.34M $4.26 39.74 Stevanato Group €1.23B 5.19 €158.21M €0.56 37.47

Is ICLR or STVN more profitable?

Stevanato Group has a net margin of 10.99% compared to Icon's net margin of 3.99%. Stevanato Group's return on equity of 10.43% beat Icon's return on equity. Company Net Margins Return on Equity Return on Assets Icon 3.99% 8.02% 4.56% Stevanato Group 10.99% 10.43% 6.16%

Does the media refer more to ICLR or STVN?

In the previous week, Stevanato Group had 4 more articles in the media than Icon. MarketBeat recorded 8 mentions for Stevanato Group and 4 mentions for Icon. Icon's average media sentiment score of 1.76 beat Stevanato Group's score of 0.54 indicating that Icon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Icon 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Stevanato Group 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate STVN or TECH?

Bio-Techne has a consensus price target of $68.92, indicating a potential downside of 4.43%. Given Bio-Techne's higher probable upside, analysts clearly believe Bio-Techne is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stevanato Group 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.86 Bio-Techne 0 Sell rating(s) 15 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.12

Does the media refer more to STVN or TECH?

In the previous week, Bio-Techne had 1 more articles in the media than Stevanato Group. MarketBeat recorded 9 mentions for Bio-Techne and 8 mentions for Stevanato Group. Bio-Techne's average media sentiment score of 1.26 beat Stevanato Group's score of 0.54 indicating that Bio-Techne is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stevanato Group 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bio-Techne 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Stevanato Group (STVN) Competitors

€20.98 +0.03 (+0.15%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

€20.88 -0.10 (-0.49%)

As of 09/11/2026 07:30 PM Eastern

Compare

STVN vs. MEDP, RVTY, CRL, ICLR, and TECH

Should you buy Stevanato Group stock or one of its competitors? Stevanato Group's main competitors and comparable companies include Medpace (MEDP), Revvity (RVTY), Charles River Laboratories International (CRL), Icon (ICLR), and Bio-Techne (TECH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Stevanato Group compare to Medpace?

Medpace (NASDAQ:MEDP) and Stevanato Group (NYSE:STVN) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

Medpace has higher revenue and earnings than Stevanato Group. Medpace is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.48	$451.12M	$17.06	34.44
Stevanato Group	€1.23B	5.19	€158.21M	€0.56	37.47

In the previous week, Medpace had 1 more articles in the media than Stevanato Group. MarketBeat recorded 9 mentions for Medpace and 8 mentions for Stevanato Group. Medpace's average media sentiment score of 1.47 beat Stevanato Group's score of 0.54 indicating that Medpace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stevanato Group	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medpace has a net margin of 17.67% compared to Stevanato Group's net margin of 10.99%. Medpace's return on equity of 110.15% beat Stevanato Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
Stevanato Group	10.99%	10.43%	6.16%

78.0% of Medpace shares are owned by institutional investors. 20.5% of Medpace shares are owned by company insiders. Comparatively, 0.7% of Stevanato Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Medpace has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market.

Medpace presently has a consensus target price of $595.20, suggesting a potential upside of 1.31%. Given Medpace's higher probable upside, equities analysts plainly believe Medpace is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Stevanato Group	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.86

Summary

Medpace beats Stevanato Group on 14 of the 17 factors compared between the two stocks.

How does Stevanato Group compare to Revvity?

Revvity (NYSE:RVTY) and Stevanato Group (NYSE:STVN) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

In the previous week, Revvity had 15 more articles in the media than Stevanato Group. MarketBeat recorded 23 mentions for Revvity and 8 mentions for Stevanato Group. Revvity's average media sentiment score of 0.82 beat Stevanato Group's score of 0.54 indicating that Revvity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revvity	8 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stevanato Group	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revvity has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market.

Stevanato Group has a net margin of 10.99% compared to Revvity's net margin of 8.16%. Stevanato Group's return on equity of 10.43% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revvity	8.16%	8.34%	5.01%
Stevanato Group	10.99%	10.43%	6.16%

Revvity presently has a consensus target price of $116.57, indicating a potential downside of 6.34%. Given Revvity's higher probable upside, analysts clearly believe Revvity is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revvity	0 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Stevanato Group	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.86

86.7% of Revvity shares are owned by institutional investors. 0.9% of Revvity shares are owned by insiders. Comparatively, 0.7% of Stevanato Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Revvity has higher revenue and earnings than Stevanato Group. Stevanato Group is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revvity	$2.91B	4.77	$241.20M	$2.10	59.27
Stevanato Group	€1.23B	5.19	€158.21M	€0.56	37.47

Summary

Revvity beats Stevanato Group on 11 of the 17 factors compared between the two stocks.

How does Stevanato Group compare to Charles River Laboratories International?

Charles River Laboratories International (NYSE:CRL) and Stevanato Group (NYSE:STVN) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

98.9% of Charles River Laboratories International shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by company insiders. Comparatively, 0.7% of Stevanato Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Stevanato Group has lower revenue, but higher earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.00B	3.32	-$144.34M	-$4.85	N/A
Stevanato Group	€1.23B	5.19	€158.21M	€0.56	37.47

In the previous week, Stevanato Group had 4 more articles in the media than Charles River Laboratories International. MarketBeat recorded 8 mentions for Stevanato Group and 4 mentions for Charles River Laboratories International. Charles River Laboratories International's average media sentiment score of 1.28 beat Stevanato Group's score of 0.54 indicating that Charles River Laboratories International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stevanato Group	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Charles River Laboratories International has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market.

Charles River Laboratories International presently has a consensus target price of $265.69, suggesting a potential downside of 4.44%. Given Charles River Laboratories International's higher possible upside, research analysts plainly believe Charles River Laboratories International is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Stevanato Group	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.86

Stevanato Group has a net margin of 10.99% compared to Charles River Laboratories International's net margin of -5.96%. Charles River Laboratories International's return on equity of 15.75% beat Stevanato Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-5.96%	15.75%	6.51%
Stevanato Group	10.99%	10.43%	6.16%

Summary

Charles River Laboratories International beats Stevanato Group on 9 of the 17 factors compared between the two stocks.

How does Stevanato Group compare to Icon?

Icon (NASDAQ:ICLR) and Stevanato Group (NYSE:STVN) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Icon currently has a consensus target price of $170.40, suggesting a potential upside of 0.64%. Given Icon's higher probable upside, research analysts clearly believe Icon is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Icon	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.41
Stevanato Group	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.86

Icon has higher revenue and earnings than Stevanato Group. Stevanato Group is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Icon	$8.29B	1.56	$229.34M	$4.26	39.74
Stevanato Group	€1.23B	5.19	€158.21M	€0.56	37.47

In the previous week, Stevanato Group had 4 more articles in the media than Icon. MarketBeat recorded 8 mentions for Stevanato Group and 4 mentions for Icon. Icon's average media sentiment score of 1.76 beat Stevanato Group's score of 0.54 indicating that Icon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Icon	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Stevanato Group	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.6% of Icon shares are owned by institutional investors. 44.0% of Icon shares are owned by insiders. Comparatively, 0.7% of Stevanato Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Icon has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market.

Stevanato Group has a net margin of 10.99% compared to Icon's net margin of 3.99%. Stevanato Group's return on equity of 10.43% beat Icon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Icon	3.99%	8.02%	4.56%
Stevanato Group	10.99%	10.43%	6.16%

Summary

Icon beats Stevanato Group on 10 of the 17 factors compared between the two stocks.

How does Stevanato Group compare to Bio-Techne?

Stevanato Group (NYSE:STVN) and Bio-Techne (NASDAQ:TECH) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

99.0% of Bio-Techne shares are held by institutional investors. 0.7% of Stevanato Group shares are held by company insiders. Comparatively, 1.3% of Bio-Techne shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Bio-Techne had 1 more articles in the media than Stevanato Group. MarketBeat recorded 9 mentions for Bio-Techne and 8 mentions for Stevanato Group. Bio-Techne's average media sentiment score of 1.26 beat Stevanato Group's score of 0.54 indicating that Bio-Techne is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stevanato Group	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Techne	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Stevanato Group has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market.

Bio-Techne has lower revenue, but higher earnings than Stevanato Group. Stevanato Group is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	€1.23B	5.19	€158.21M	€0.56	37.47
Bio-Techne	$1.22B	9.31	$181.86M	$1.15	62.71

Bio-Techne has a net margin of 14.97% compared to Stevanato Group's net margin of 10.99%. Bio-Techne's return on equity of 13.23% beat Stevanato Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	10.99%	10.43%	6.16%
Bio-Techne	14.97%	13.23%	10.61%

Bio-Techne has a consensus price target of $68.92, indicating a potential downside of 4.43%. Given Bio-Techne's higher probable upside, analysts clearly believe Bio-Techne is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.86
Bio-Techne	0 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.12

Summary

Bio-Techne beats Stevanato Group on 13 of the 16 factors compared between the two stocks.

Get Stevanato Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STVN vs. The Competition

Export

Metric	Stevanato Group	Life Sciences Tools & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	€6.33B	€9.69B	€7.16B	€23.20B
Dividend Yield	N/A	1.47%	2.56%	3.56%
P/E Ratio	37.47	66.42	272.98	28.69
Price / Sales	5.19	287.71	654.99	102.56
Price / Cash	23.75	26.25	77.04	33.82
Price / Book	3.78	5.28	10.33	4.74
Net Income	€158.21M	€56.67B	€3.49B	€1.07B
7 Day Performance	2.60%	-2.08%	-3.33%	-1.99%
1 Month Performance	-1.35%	-1.60%	-0.42%	-2.68%
1 Year Performance	-20.61%	25.11%	19.22%	10.45%

Stevanato Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STVN Stevanato Group	2.856 of 5 stars	€20.98 +0.2%	N/A	-22.4%	€6.33B	€1.23B	37.47	6,010	Analyst Forecast
MEDP Medpace	2.5908 of 5 stars	$583.21 -1.8%	$584.18 +0.2%	+18.1%	$16.28B	$2.53B	34.19	6,200	Positive News
RVTY Revvity	2.7645 of 5 stars	$126.59 -1.6%	$110.58 -12.6%	+45.2%	$14.13B	$2.86B	60.28	11,000	News Coverage Analyst Forecast Analyst Revision High Trading Volume
CRL Charles River Laboratories International	2.0297 of 5 stars	$282.23 -2.1%	$255.65 -9.4%	+74.1%	$13.47B	$4.02B	N/A	19,700	Positive News Analyst Forecast
ICLR Icon	2.4987 of 5 stars	$161.40 -2.2%	$170.40 +5.6%	-3.3%	$12.36B	$8.25B	37.89	40,100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:STVN) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stevanato Group (STVN) Competitors

STVN vs. MEDP, RVTY, CRL, ICLR, and TECH

How does Stevanato Group compare to Medpace?

Summary

How does Stevanato Group compare to Revvity?

Summary

How does Stevanato Group compare to Charles River Laboratories International?

Summary

How does Stevanato Group compare to Icon?

Summary

How does Stevanato Group compare to Bio-Techne?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STVN vs. The Competition

Stevanato Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Stevanato Group (STVN) Competitors

STVN vs. MEDP, RVTY, CRL, ICLR, and TECH

How does Stevanato Group compare to Medpace?

Which has stronger earnings & valuation, MEDP or STVN?

Does the media prefer MEDP or STVN?

Is MEDP or STVN more profitable?

Do insiders & institutionals hold more shares of MEDP or STVN?

Which has more volatility & risk, MEDP or STVN?

Do analysts rate MEDP or STVN?

Summary

How does Stevanato Group compare to Revvity?

Does the media refer more to RVTY or STVN?

Which has more risk & volatility, RVTY or STVN?

Is RVTY or STVN more profitable?

Do analysts rate RVTY or STVN?

Do institutionals & insiders believe in RVTY or STVN?

Which has stronger valuation and earnings, RVTY or STVN?

Summary

How does Stevanato Group compare to Charles River Laboratories International?

Do insiders and institutionals hold more shares of CRL or STVN?

Which has stronger earnings and valuation, CRL or STVN?

Does the media favor CRL or STVN?

Which has more volatility & risk, CRL or STVN?

Do analysts prefer CRL or STVN?

Is CRL or STVN more profitable?

Summary

How does Stevanato Group compare to Icon?

Do analysts recommend ICLR or STVN?

Which has better earnings and valuation, ICLR or STVN?

Does the media refer more to ICLR or STVN?

Do insiders & institutionals have more ownership in ICLR or STVN?

Which has more volatility and risk, ICLR or STVN?

Is ICLR or STVN more profitable?

Summary

How does Stevanato Group compare to Bio-Techne?

Do institutionals and insiders believe in STVN or TECH?

Does the media refer more to STVN or TECH?

Which has more volatility and risk, STVN or TECH?

Which has better valuation & earnings, STVN or TECH?

Is STVN or TECH more profitable?

Do analysts rate STVN or TECH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STVN vs. The Competition

Stevanato Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools